2021
-
Multidisciplinary EURACAN/IASLC Proposal for Revision of the Histologic Classification of Malignant Pleural Mesothelioma
Sponsored by EURACAN and the IASLC, a multidisciplinary group comprised of pathologists, oncologists, surgeons, radiologists, and molecular biologists met July 5 and 6, 2018, to critically review the current histologic […]
-
Controversy Regarding U.S. Marketing of New Heated Tobacco Product IQOS
Heated tobacco products (HTPs) are a growing category of novel tobacco products. They typically consist of an electronic heating component and a tobacco insert in the form of a cigarette-like […]
-
A New Year’s Resolution to Promote the Use of Patient-Sensitive Language
In 2021, people living with lung cancer and their caregivers will likely be attending virtual oncology conferences such as the 2020 WCLC and making deep dives into research in record […]
-
WCLC Conference Chairs Offer Insights on The New All-Virtual Program, The Year Ahead
The Chairs of the 2020 World Conference on Lung Cancer, all based in Asia, had originally designed a live program to be hosted in Singapore. The outbreak of COVID-19 forced […]
-
2020 Adi F. Gazdar IASLC Merit Award Recipient: Dr. Alex A. Adjei
Alex A. Adjei, MD, PhD, is a Professor of Oncology and Professor of Pharmacology in the Mayo College of Medicine. He has had a passion for drug development in cancer, […]
-
Role of Thai Oncology Pharmacists in Lung Cancer Treatment: A Q&A With Dr. Suthan Chanthawong
Suthan Chanthawong, BPharm, BCP, BCOP, is an assistant professor of Pharmaceutical Sciences in the Division of Clinical Pharmacy at Khon Kaen University, in Thailand. In the following interview, he discusses […]
-
PD-L1 Blockade Reinvigorates Dendritic Cells for Antitumor Immunity
In reference to: Mayoux M, Roller A, Pulko V, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12(534):eaav7431. Checkpoint blockade with PD-1 or PD-L1 […]
-
Research’s Race to Stop a Pandemic
Experts discuss how a global pandemic is putting pressure on traditional methods of research dissemination. A search on PubMed.gov for COVID-19 reveals 93,851 results as of Mid-January 2021. “To put […]
-
Should We Delay Lung Cancer Screening During the COVID-19 Pandemic?
To address the issue of low-dose CT screening, during the COVID-19 pandemic, for lung cancer and management of both screen-detected nodules and incidentally detected nodules, various eminent organizations and expert […]
-
Improving Molecular Testing in Lung Cancer: What We Learned From the IASLC Global Survey
The past 10 years have seen a dramatic increase in novel therapeutic options for patients with lung cancer, with many treatments now personalized to the specific tumor characteristics of each […]
View ILCN Archives
Provider Resources